The human urinary proteome provides an assessment of kidney injury with specific biomarkers for different kidney injury phenotypes. In an effort to fully map and decipher changes in the urine proteome and peptidome after kidney transplantation, renal allograft biopsy matched urine samples were collected from 396 kidney transplant recipients. Centralized and blinded histology data from paired graft biopsies was used to classify urine samples into diagnostic categories of acute rejection, chronic allograft nephropathy, BK virus nephritis, and stable graft. A total of 245 urine samples were analyzed by liquid chromatography-mass spectrometry using isobaric Tags for Relative and Absolute Quantitation (iTRAQ) reagents. From a group of over 900 proteins identified in transplant injury, a set of 131 peptides were assessed by selected reaction monitoring for their significance in accurately segregating organ injury causation and pathology in an independent cohort of 151 urine samples. Ultimately, a minimal set of 35 proteins were identified for their ability to segregate the 3 major transplant injury clinical groups,-comprising the final panel of 11 urinary peptides for acute rejection (93% AUC), 12 urinary peptides for chronic allograft nephropathy (99% AUC), and 12 urinary peptides for BK virus nephritis (83% AUC). Thus, urinary proteome discovery and targeted validation can identify urine protein panels for rapid and non-invasive differentiation of different causes of kidney transplant injury, without the requirement of an invasive biopsy. 
INTRODUCTION
Kidney transplantation is the optimal choice of treatment for end-stage kidney disease 1 . Despite improved short-term outcomes 2 , long-term outcomes and graft survival rates remain suboptimal 2, 3 . Recent studies by our group and others have demonstrated that sub-clinical inflammation followed by tissue injury is an ongoing process in the transplanted kidney, and is a primary cause of graft loss [4] [5] [6] [7] . This injury cannot be identified by the currently used clinical biomarkers-serum creatinine and increased urine protein load, or proteinuria. Both markers reflect non-specific and late organ injury, and cannot distinguish between causes of graft dysfunction that may require diametrically opposed approaches to therapy, such as immunosuppression intensification for graft rejection and immunosuppression reduction for BK viral nephritis. Both entities, if untreated, result in chronic tubulointerstitial loss and fibrosis 2, 8 .
In this study, we have continued our efforts [9] [10] [11] [12] [13] to fully map and decipher changes in the urine proteome and peptidome after kidney transplantation, and to understand the perturbations in specific proteomic panels in the urine during biopsy-confirmed injury to the organ, defined by acute rejection (AR) 2 , BK viral nephritis (BKVN) 14 , and chronic allograft nephropathy (CAN) 15 versus stable renal allograft (STA) 15 . In addition, we have evaluated the biological processes that drive these specific injuries, and assessed variances in perturbations of transcriptional and translational programs in graft and urine samples from the same patient.
RESULTS

Transplant injury-specific proteins segregate transplant injuries by proteomics using either iTRAQ-based or label-free LC-MS in 264 unique urine samples analyzed by different methodologies and in independent sample sets
Application of a 2D-LC-MS/MS strategy using iTRAQ reagents on 108 urine samples pooled into 6 pools/phenotype (5 independent phenotype specific samples for AR, CAN and STA and 4 3 independent urine samples for BKVN (due to limited available cases)), identified a total of 6379 unique peptides (false discovery rate, FDR <0.1%), spanning 958 unique human proteins (Supplemental Table S1A ) 13 . Principal component analysis (PCA) of this data ( Figure 1A) demonstrated that urine proteins generally segregate samples with injuries from stable grafts and also clustered sample groups into different phenotypes. Within this cluster of proteins, fibrinogen β and fibrinogen ɣ have been previously confirmed by independent ELISA validation to be significantly (p<0.05) elevated in AR over the other injury phenotypes 13 . This approach allowed for interrogation of the dynamic range of protein abundance measurements in transplant dysfunction categories prior to proceeding with larger numbers of individual samples to be analyzed by label-free LC-MS and SRM.
The label-free LC-MS datasets from 137 individual samples identified 26,462 peptides mapped to 2,291 proteins. Each peptide was evaluated to determine if there was adequate data for an
Analysis of Variance or a qualitative G-test 16 . Outlier and contaminant data were filtered using the log2 robust Mahalnobis distance 17 . Thus, at the end of filtering and outlier discovery there were 133 samples associated with 16,218 human peptides from 1,574 proteins. PCA demonstrated that these proteins cluster to separate injuries from stable grafts, and also show scatter differences based on different injury phenotypes ( Figure 1B ).
Urine proteins uncover biological mechanisms of graft injury
A significant number (n=811) of the total proteins (n=1719) identified were impacted during kidney graft injury (Supplemental Table S1B and S1C). Major changes were noted for major molecular processes in transplant injury: the immune response (n=179 proteins; p=4.01E-23, response to external stimulus (n=224, p=5.68E-24), and extracellular matrix organization (n=118, p=2.05E-51) (Supplemental Table S1B ). A total of 517 urine proteins were significantly dysregulated in AR; 228 were increased and 289 were decreased in AR compared to other 5 clinical categories (p<0.05) (Supplemental Table S1C ), and were uniquely enriched for regulation of cell adhesion (n=51, p=2.98E-17), wound healing (n=48, p=2.45E-12), regulation of body fluid levels (n=47,1.68E-11) (Supplemental Table S1D Table S1D ). Significant, and somewhat BKVN-specific urinary protein alterations were seen in lactotransferrin (TRFL), SUMO2 (SUMO2), granulins (GRN), haptoglobin related protein (HPTR), peptidase inhibitor 16 (PI16), alpha-1-antitrypsin (A1AT) and fibulin-1 (FBLN1).
Evaluation of transcriptomic data from matching urine and graft biopsies within patients shows specific overlapping and unique molecular processes in transplant injury
Out of 811 proteins that were identified as significantly changed in the urine protein dataset (Supplemental Table S1C ), 26% (n=153) were also dysregulated at the mRNA level in the ). Due to the smaller number of BKVN samples, these were all included in a single sample group to retain analysis power. As seen in Figure 3A , there were overall differences in Validation Set 1 samples, seen across the majority of peptides sampled (n=100), segregating transplant injury overall from stable samples (filter of >2 fold change and p <0.01 for transplant injury (Supplemental Table S1E ). From the subset of perturbed proteins in transplant injury, using AltAnalyze (www.altanalyze.org), a smaller subset of 35 peptides from 33 proteins was identified (Table 2) personalization. This will also aid in mitigating transplant injury and guide optimal immunosuppression dosing.
Biomarker discovery and validation is inherently an arduous task because of issues including sample selection data analysis, patient heterogeneity, and other physiological confounders 11, 18, 20 . Here, we use cutting edge technological assays, controlled study design, and customized bioinformatics to identify panels of proteins that may be used as fingerprints of AR, BKVN, and , may result in the evolution of "escape" mechanisms seen in chronic graft injury. An earlier urine proteomic biomarker study published by our group used 9 a MALDI-TOF based "peptidomic" approach of analyzing protein digestion patterns from the activation of various proteases in urine during acute rejection. Though this previous study only focused on examining very small peptides <10 kDa after selective filtration, which is different from our study that now interrogates a different proteomic fraction of urine that is >10
kDa. There is a significant overlap of proteins (87%) identified in this study and another recent publication by our group, which uses the same approach on a smaller sample set that only contains AR and STA sample analysis 13 . More than two thirds of the proteins and peptides in this latter paper overlap with the current dataset in acute rejection. In this current study, the analysis of additional categories of graft dysfunction allows for the discovery of additional markers that now more fully map major categories of graft dysfunction.
CONCLUSIONS
In conclusion, years of carefully archiving urine samples collected with standardized protocols 10, 12, 25 , matched with graft biopsies, and read by centralized histology 26 , as well as a "back to basics" approach of whole proteome discovery using unbiased methods, resulted in biologically relevant information on graft injury. The bird's eye view picture confirms our basic understanding of immune injury mechanisms, but a more granular view now provides details on critical players in these pathways that deserve closer attention. The limitations of the study mainly reside in the high cost and restricted availability of mass spectromery instrumentation. Given the experiment costs, we used a pooling strategy approach for the iTRAQ discovery to reduce the number of experiments, while retaining a larger sample analyte cohort. This could have potentially eliminated underlying disease heterogeneity of individual samples and "smoothened" out some biologically important signals that could track with disease severity in each classification class.
Though this pooling approach can reduce the statisitcal power for discovery and limit extrapolation of data, the inclusion of individual samples, without pooling, in the validation cohort, allowed for very stringent analysis of a more restricted and smaller set of biomarkers. In addition, the deliverable of an SRM based panel to quantitatively measure the level of peptides to direct physicians to make decisions on transplant injury, impose the necessity of an available mass spectrometer in a clinical lab or hospital testing site, though these machines are now becoming increasingly availabile at lower costs. We propose to work on developing ELISA 
Urine collection, processing, and storage
We optimized our urine collection, processing, and storage protocols for proteomic studies from multiple clinical sites in our large biobank of urine samples 33, 11, 13 . Second morning void mid-
12
stream urine samples were collected and centrifuged at room temperature. All the urine samples in this study were collected prior to the biopsies. The detailed method is available in Supplemental Methods.
Discovery of urine proteomic repertoires by quantitative iTRAQ proteomics with a novel pooled sample approach and independent validation of phenotype specific proteins by shotgun proteomics using LC-MS/MS
To identify the repertoire and abundance range of proteins that were perturbed after transplantation of an HLA mismatched kidney, as well as their further alterations during immunological injury from innate (viral) or alloimmunity, we used a novel pooling approach for each distinct injury phenotype, with multiple samples/pool to control for pool heterogeneity 13 .
We prepared 
Independent validation of most informative phenotype specific peptides by customized LC-SRM assays
Data analyses
Peptides from iTRAQ-based assay were identified based on tandem MS/MS spectra using the Sequest search algorithm against a human protein database (UniprotKB, released 2010-05).
Details of peptide identification criteria for all LC-MS-based assays is available in the Supplemental Methods.
Data analysis for LC-SRM data. The data was analyzed with Skyline software 34 . The best transition, highest in intensity and lowest in noises, was selected and used for quantification.
The ratio of endogenous to heavy isotope-labeled internal standard was normalized with protein load and urine creatinine to achieve relative abundance of the peptide in the urine. All data analysis was performed under R 3.1.2 (http://www.r-project.org/). Data were log(2) transformed and quantile normalized. The batch effect was adjusted by empirical Bayes methods 35 .
Clustering heatmaps were drawn by computing correlation similarity metric and average linkage distance 36 . Confounder analysis was done to eliminate any association between injury 14 phenotypes and demographic parameters. Recipient ag patients' phenotypes with a p-value < 0.001. We evaluated correlation of potential biomarker (log-transformed) and recipients' age, however there was no significant association found cell and T cell) was examined by using the geometric means of significant genes for each phenotype by Fisher's exact test, using a significance threshold of p<0.05.
Intra-patient variances in tissue mRNA versus urine protein levels in transplant injury.
Gene expression data for AR, CAN, and BKVN specific genes from kidney biopsy data (GEO GSE75693), were used to map 811 proteins that were identified as significantly altered in injury phenotypes AR, CAN, and BKVN, utilizing microarray data from matching biopsies from the same patient at the same time-point. The functional enrichment analysis was performed by using STRING database (http://string-db.org) 39 . The p value were false discovery rate (fdr) adjusted. 
